Author(s): Purna Chandra Reddy Guntaka* and Srinivas Lankalapalli
Telaprevir acts against the virus that causes hepatitis C infection and is used to treat chronic hepatitis C infection in adult patients (aged 18–65 years) in combination with peginterferon alfa and ribavirin. Telaprevir is available as tablet at the dose of 375 mg in the market under the brand name of incivik. The primary aim of the study was to develop a pharmaceutically equivalent, stable, robust and quality improved formulation of tablets. Telaprevir is having very low solubility, which will reduce the bioavailability of the dosage form hence premix of telaprevir was prepared by spray drying using combination of hypromellose acetate succinate (HPMC-AS) and different surfactants sodium lauryl sulphate (SLS), Polysorbate-80, Docusate sodium as carriers. Further the spray dried telaprevir was formulated into tablets and evaluated. Among the tablets formulation F3 containing HPMC-AS and SLS as carrier demonstrated better drug release comparable to that of the innovator. Hence the present study clearly indicated usefulness of spray drying technology in improving the dissolution rate of telaprevir.